



COMMUNICATIONS POLICY

Policy Objective

To ensure all shareholders, potential investors and other stakeholders are informed in a timely manner of all major developments effecting Bionomics Limited through a systematic communications process.

1. Key Considerations

Continuous Disclosure requirements under ASX listing rules are an essential element to this communication process. The Company has developed and issued its Disclosure Policy which is available through the Corporate Governance section of its website. This policy should be read in conjunction with the Disclosure Policy

The Annual General Meeting, Annual Report, announcements to the ASX and the Company web site are considered the primary communication vehicles within the context of this communications policy.

In addition, reasonable access to senior management and directors will be provided for shareholders, potential investors and other stakeholders to seek information on the business.

2. Annual General Meetings

The Company intent is to encourage full participation of shareholders at the Annual General Meeting and other shareholder meetings conducted by the Company. This is to ensure a high level of accountability and clarity around the business strategy and performance. At each meeting, shareholders, through the Chairman, will be given the opportunity to ask general questions of directors and senior management. The Company will also ensure that its external auditors attend the Annual General Meeting and will be available to answer questions about the conduct of the audit and the preparation and content of the Auditors Report.

In addition to the lodgement of notice of meeting with the ASX and mailing to shareholders, the Company will also put such notices on the Company's website on the date the documents are posted to shareholders. Results of resolutions tabled at shareholder's meetings will be lodged with the ASX and will also be available on the website as soon as practical after the relevant shareholder meeting.

Wherever possible, when drafting notices relating to shareholder meetings, the Company shall adopt the "Guidelines for Notices of Meeting" set out in the ASX Corporate Governance Council Guidelines for Notices of Meeting (July 2014).

3. Written Communications

In all written communication the Company will seek to ensure concise and accurate presentation of information on the business taking into consideration not only the present document but also prior information issued to shareholders.

With regard to the Annual Report the Company will strive to ensure that this document clearly and concisely documents Bionomics' business strategy, its achievements and its financial performance and position in addition to meeting all legal requirements associated with such annual reports required by the relevant legal bodies such as the Corporations Act, ASIC and ASX Listing Rules.

4. Electronic Communications

The Company website is structured as the key day to day information resource for shareholders, potential investors and other stakeholders and hence will be regularly updated to ensure that the information remains current.

All information will be securely lodged on the website with controlled access and edit capabilities. Any downloads by web site users are to be only in secure format such as pdf files.

All announcements and filings lodged with the ASX, other than securities trading announcements and quarterly reports (Appendix 4C), will be lodged on the Company's website on a timely basis and on the OTCQX page (Code BNOEF) under the News or Filings & Disclosures tabs.

The Company may also make available additional information to shareholders via the website such as presentations to industry conferences or broker presentations.

Announcements using the Company's Social Media platform (Twitter, LinkedIn, social media email) will comply with BNO 58 Social Media Position Statement and this Communications Policy where Social Media is used to communicate Bionomics news or information.

5. Access to Directors and Management

Shareholders, potential investors and other stakeholders will have reasonable access to selected senior management and directors of the Company in order to ask direct questions or to seek additional information on the business. Requests for additional information may be made through the website, or by mail or phone to the Company's registered office using the free call facility. Contact details for these communication access points are as follows:

- Web Site Address www.bionomics.com.au
- Registered Office 31 Dalglish Street
Thebarton
South Australia 5031
- FreeCall Number 1800 354 610
- Direct call +61 8 8354 6100

Senior management able to provide information on the Company is restricted to:

- CEO and Managing Director Dr Deborah Rathjen
- Chief Financial Officer Mr Steven Lydeamore
- Legal Counsel & Company Secretary Mr Jack Moschakis

Directors and senior management must ensure they continue to observe all requirements of the Disclosure Policy in any communication and ensure they only

make comments in their areas of expertise or after appropriate consultation with the relevant staff within the business in conjunction with the CEO. Discussion should focus on publicly announced facts regarding the business and should not in any way contain comments which could be construed as investment advice.

6. Safe Harbour Statements

A safe harbour statement is to be included in ASX announcements, media releases and all Company presentations and briefing materials, where appropriate. The safe harbour statement is to be principally in accordance with the sample set out below:

Factors Affecting Future Performance

This [announcement / press release] contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this [announcement / presentation].